Vaccine for the prevention of poliomyelitis (Vaccinum ad prophylaxim poliomyelitidis)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Vaccines, serums, phages and toxoids

Included in the formulation
  • BiVac polio (polio vaccine oral, divalent, live attenuated 1, 3 types)
    solution inwards 
    The enterprise for the production of bacterial and viral preparations of the Institute of Poliomyelitis and Viral Encephalitis. M.P.Chumakov RAMS FSUE     Russia
  • Vaccine poliomyelitis oral 1, 2 and 3 types
    solution inwards 
    The enterprise for the production of bacterial and viral preparations of the Institute of Poliomyelitis and Viral Encephalitis. M.P.Chumakov RAMS FSUE     Russia
  • Imovax Polio
    suspension w / m PC 
    Sanofi Pasteur S.A.     France
  • POLYMILEX® vaccine for inactivated poliomyelitis prevention
    suspension w / m PC 
    NANOLEC, LTD.     Russia
  • Polyoriks®
    solution w / m 
    GlaxoSmithKline Trading, ZAO     Russia
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    J.07.B.F   Vaccines for the prevention of poliomyelitis

    J.07.B.F.03   The virus of poliomyelitis is trivalent inactivated

    Pharmacodynamics:

    The vaccine against polioviruses 1, 2 and 3 types. Obtained from polioviruses of three types, cultivated on the BERO cell line and inactivated with formalin.

    This vaccine causes the production of a significant number of neutralizing antibodies to polioviruses,starting with the second injection, regardless of the general condition of the vaccinated persons (immunodeficiency, bowel disease, dystrophy). Immunity to poliomyelitis viruses is acquired after the 3rd injection of the vaccine, is strengthened with subsequent injections and persists for at least 5 years after the first revaccination.

    After the introduction of three doses of this vaccine seroconversion is observed in 95-100% of individuals.

    Pharmacokinetics:

    No data.

    Indications:

    Prevention of poliomyelitis.

    ICD-10

    XXI.Z20-Z29.Z24.0   The need for immunization against poliomyelitis

    Contraindications:

    Acute infectious diseases; allergic reactions to streptomycin.

    Carefully:

    No data.

    Pregnancy and lactation:

    No data.

    Dosing and Administration:

    The vaccine is administered subcutaneously or intramuscularly. Primary vaccination is carried out by 3 consecutive injections of this vaccine at intervals of 1 month. For one administration - 1 dose of vaccine. Revaccination is carried out 1 year after completion of the course of primary vaccination, then every 5-10 years.

    Side effects:

    Not identified.

    Overdose:

    No data.

    Interaction:

    The vaccine can be used in combination with other injectable forms of vaccines: for the prevention of diphtheria, tetanus,whooping cough, infections caused by Haemophilus influenzae type b, and hepatitis B.

    Special instructions:

    This vaccine can be used in combination with other vaccines for injection, including vaccines for the prevention of diphtheria, tetanus, whooping cough, hepatitis B and infections caused by Haemophilus influenzae type b.

    Instructions
    Up